April 30 (Reuters) - The U.S. Food and Drug

Administration (FDA) has approved the granule formulation of

Neurocrine Biosciences' ( NBIX ) INGREZZA drug to treat movement

disorders associated with Huntington's disease, the company said

on Tuesday.

Huntington's disease is an inherited condition that causes

the progressive breakdown of nerve cells in the brain, resulting

in a gradual decline in motor control, cognition and mental

stability.

INGREZZA was first approved in 2017 in its oral capsule

formulation to treat adults with movement disorders tardive

dyskinesia and chorea.

The granule formulation, INGREZZA SPRINKLE, was

developed as an alternative for patients with tardive dyskinesia

and chorea who face difficulty swallowing capsules.

The company, however, did not disclose the pricing and

availability of the drug.